InvestorsHub Logo
Followers 53
Posts 3355
Boards Moderated 0
Alias Born 10/26/2013

Re: antihama post# 2267

Friday, 09/14/2018 6:00:16 PM

Friday, September 14, 2018 6:00:16 PM

Post# of 3283
What, Cheng didn't take the Spectrum CMO job??? Getting to be President and CEO might explain it (another is that SPPI is not looking for a CMO anymore).

After serving as Gilead’s chief medical officer for just six months, Andrew Cheng, M.D., Ph.D., has taken the top spot at Akero Therapeutics, not long after the biotech raised $65 million to move its lead nonalcoholic steatohepatitis candidate into phase 2 trials in the middle of next year.

And with the new president and CEO, Akero will relocate its headquarters from Cambridge, Massachusetts, to San Francisco, where Cheng is based. The company’s former CEO and co-founder, Jonathan Young, J.D., Ph.D., will stay on as executive VP and chief operating officer.

“Andrew's appointment as president and CEO builds on the incredible momentum at Akero this past year,” Aaron Kantoff, Akero board member and principal at Apple Tree Partners, which helped lead June’s series A round, said in a release. “The ability of the company to attract someone of Andrew's caliber is a testament to the groundwork laid by the founding team.” - FierceBiotech